Genfit S.A. (GNFT)
NASDAQ: GNFT · Real-Time Price · USD
4.270
-0.030 (-0.70%)
May 12, 2025, 4:00 PM - Market closed
Genfit Revenue
In the year 2024, Genfit had annual revenue of 70.69M EUR with 105.01% growth. Genfit had revenue of 9.59M in the half year ending December 31, 2024, a decrease of -32.01%.
Revenue (ttm)
70.69M EUR
Revenue Growth
+105.01%
P/S Ratio
2.99
Revenue / Employee
444,604 EUR
Employees
159
Market Cap
219.10M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 70.69M | 36.21M | 105.01% |
Dec 31, 2023 | 34.48M | 8.24M | 31.38% |
Dec 31, 2022 | 26.25M | -59.11M | -69.25% |
Dec 31, 2021 | 85.36M | 76.67M | 883.14% |
Dec 31, 2020 | 8.68M | -30.29M | -77.72% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GNFT News
- 5 days ago - GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents - GlobeNewsWire
- 7 days ago - GENFIT to Present Latest ACLF Research at EASL Congress 2025 - GlobeNewsWire
- 13 days ago - GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F - GlobeNewsWire
- 14 days ago - GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025 - GlobeNewsWire
- 18 days ago - GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2 - Benzinga
- 7 weeks ago - GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders - GlobeNewsWire
- 2 months ago - Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs - GlobeNewsWire